Haemonetics Corp. Secures New Credit for Strategic Growth
Company Announcements

Haemonetics Corp. Secures New Credit for Strategic Growth

Haemonetics Corp. (HAE) has issued an announcement.

Haemonetics Corporation revamped its financing structure by entering into a new credit agreement that refines the terms of its 2022 agreement with JPMorgan Chase Bank. The updated deal secures a $250 million term loan and boosts its revolving credit facility to $750 million. This financial maneuver is set to extend the company’s credit maturity to April 2029, offering a flexible interest rate tied to the SOFR Rate plus an additional percentage contingent on the company’s leverage ratio. Additionally, the agreement outlines financial covenants and allows for certain debt exclusions, providing Haemonetics with strategic leverage for future growth and investments.

For an in-depth examination of HAE stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyHaemonetics upgraded to Strong Buy from Outperform at Raymond James
TipRanks Auto-Generated NewsdeskHaemonetics’ Q2 2025 Earnings Show Strong Growth
TheFlyHaemonetics backs FY25 adjusted EPS view $4.45-$4.75, consensus $4.59
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App